Recent advances in the phencyclidine model of schizophrenia

American Journal of Psychiatry

Volumn 148, Issue 10, 1991, Pages 1301-1308

  Javitt, Daniel C ^a,b   Zukin, Stephen R ^a  

^a Bronx Psychiatric Center   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR STIMULATING AGENT; AMPHETAMINE; ANTIDEPRESSANT AGENT; DIZOCILPINE; HALOPERIDOL; KETAMINE; N METHYL DEXTRO ASPARTIC ACID; NEUROLEPTIC AGENT; PHENCYCLIDINE;

CONFERENCE PAPER; HALLUCINATION; HUMAN; MODEL; MOTOR RETARDATION; ORAL DRUG ADMINISTRATION; PARANOIA; PRIORITY JOURNAL; SCHIZOPHRENIA; WITHDRAWAL SYNDROME;

ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMAN; MEMORY; MICE; PAIRED-ASSOCIATE LEARNING; PHENCYCLIDINE; PHENCYCLIDINE ABUSE; RECEPTORS, N-METHYL-D-ASPARTATE; RECEPTORS, NEUROTRANSMITTER; RECEPTORS, PHENCYCLIDINE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0025952455     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/ajp.148.10.1301     Document Type: Article

References (95)

1. Sayed Y, Garrison JM: The dopamine hypothesis of schizophrenia and the antagonistic action of neuroleptic drugs-a review. Psychopharmacol Bull 1983; 19:283-288
2. Luby ED, Gottlieb JS, Cohen BD, Rosenbaum G, Domino EF: Model psychoses and schizophrenia. Am J Psychiatry 1962; 119: 61-67
3. Collins VJ, Gorospe CA, Rovenstine EA: Intravenous nonbarbiturate, nonnarcotic analgesics: preliminary studies. I. Cyclohexylamines. Anesth Analg 1960; 39:303-306
4. Greifenstein FE, Yoskitake J, DeVault M, Gajewski JE: A study of 1-aryl-cyclohexylamine for anesthesia. Anesth Analg 1958; 37:283-294
5. Johnstone M, Evans V, Baigel S: Sernyl (Cl-395) in clinical anesthesia. Br J Anaesth 1958; 31:433-439
6. Corssen G, Domino EF: Dissociative anesthesia: further pharmacologic studies and first clinical experience with the phencyclidine derivative CI-581. Anesth Analg 1966; 45:29-40
7. Meyer JS, Greifenstein F, DeVault M: A new drug causing symptoms of sensory deprivation. J Nerv Ment Dis 1959; 129:54-61
8. Bakker CB, Amini FB: Observations on the psychotomimetic effects of Sernyl. Compr Psychiatry 1961; 2:269-280
9. Luby ED, Cohen BD, Rosenbaum F, Gottlieb J, Kelley R: Study of a new schizophrenomimetic drug, Sernyl. Arch Neurol Psychiatry 1959; 81:363-369
10. Ban TA, Lohrenz JJ, Lehmann HE: Observations on the action of Sernyl - a new psychotropic drug. Can Psychiatr Assoc J 1961; 6:150-156
11. Davies BM, Beech HR. The effect of 1-arylcyclohexylamine (Sernyl) on twelve normal volunteers. J Ment Sci 1960; 106: 912-924
12. Domino EF, Luby E: Abnormal mental states induced by phencyclidine as a model of schizophrenia, in PCP (Phencyclidine): Historical and Current Perspectives. Edited by Domino EF. Ann Arbor, NPP Books, 1981
13. Rodin EA, Luby ED, Meyer JS: Electroencephalographic findings associated with Sernyl infusion. EEC Clin Neurophysiol 1959; 11:796-798
14. Rosenbaum G, Cohen BD, Luby ED, Gottlieb JS, Yelen D: Comparisons of Sernyl with other drugs. Arch Gen Psychiatry 1959; 1:651-656
15. Cohen BD, Rosenbaum G, Luby ED, Gottlieb JS: Comparison of phencyclidine hydrochloride (Sernyl) with other drugs. Arch Gen Psychiatry 1961; 6:79-85
16. Berman KF, Illowsky BP, Weinberger DR: Physiological dysfunction of dorsolateral prefrontal cortex in schizophrenia. Arch Gen Psychiatry 1988; 45:616-622
17. Kolb B, Whishaw IQ: Performance of schizophrenic patients on tests of right frontal, temporal or parietal functioning in neurological patients. J Nerv Ment Dis 1983; 171:435-443
18. Itil T, Keskiner A, Kiremitci N, Holden JMC: Effect of phencyclidine in chronic schizophrenics. Can Psychiatr Assoc J 1967; 12:209-212
19. Kornetsky C: Hyporesponsivity of chronic schizophrenic patients to dextroamphetamine. Arch Gen Psychiatry 1976; 33: 1425-1428
20. Angrist B, Peselow E, Rubinstein M, Corwin J, Rotrosen J: Partial improvement in negative schizophrenic symptoms after amphetamine. Psychopharmacology (Berlin) 1982; 78:128-130
21. Burns RS, Lerner SE: Perspectives: acute phencyclidine intoxication. Clin Toxicol 1976; 9:477-501
22. Allen RM, Young SJ: Phencyclidine-induced psychosis. Am J Psychiatry 1978; 135:1081-1084
23. Rainey JM, Crowder MK: Prolonged psychosis attributed to phencyclidine: report of three cases. Am J Psychiatry 1975; 132: 1076-1078
24. McCarron MM, Schulze BW, Thompson GA, Concer MC, Goetz WA: Acute phencyclidine intoxication: clinical patterns, complications, and treatment. Ann Emerg Med 1981; 10:290-297
25. Erard R, Luisada PV, Peele R: The PCP psychosis: prolonged intoxication or drug-precipitated functional illness? J Psychedelic Drugs 1980; 12:235-245
26. Yesavage JA, Freeman AM III: Acute phencyclidine (PCP) intoxication: psychopathology and prognosis. J Clin Psychiatry 1978; 44:664-665
27. Lieberman JA, Kane JM, Alvir J: Provocative tests with psychostimulant drugs in schizophrenia. Psychopharmacology 1987; 91:415-433
28. Cook CE, Perez-Reyes M, Jeffcoat AR, Drin DR: Phencyclidine disposition in humans after small doses of radiolabelled drug. Fed Proc 1983; 42:2566-2569
29. Walberg CB, McCarron MM, Schulze BW: Quantitation of phencyclidine in serum by enzyme immunoassay: results in 405 patients. J Anal Toxicol 1983; 7:106-110
30. Pearce DS: Detection and quantitation of phencyclidine in blood by use of [2H5]phencyclidine and select ion monitoring applied to non-fatal cases of phencyclidine intoxication. Clin Chem 1976; 22:1623-1626
31. Marshman JA, Ramsay MP, Seller EM: Quantitation of phencyclidine in biological fluids and application to human overdose. Toxicol Appl Pharmacol 1976; 35:129-136
32. Liden CB, Lovejoy FH, Costello CE: Phencyclidine: nine cases of poisoning. JAMA 1975; 234:513-516
33. Donaldson JO, Baselt RC: CSF phencyclidine. Am J Psychiatry 1979; 136:1341-1342
34. Foster HM, Narasimhachari N: Phencyclidine in CSF and serum: a case of attempted filicide by a mother without a history of substance abuse. J Clin Psychiatry 1986; 47:428-429
35. Rothman S: Noncompetitive N-methyl-D-aspartate antagonists affect multiple ionic currents. J Pharmacol Exp Ther 1988; 246:137-142
36. Albuquerque EX, Aguayo LG, Warnick JE, Ickowicz RK, Blaustein MP: Interactions of phencyclidine with ion channels of nerve and muscle: behavioral inplications. Fed Proc 1983; 42: 2584-2589
37. Schwartz RD, Mindlin MC: Inhibition of the GABA receptorgated chloride channel in brain by noncompetitive inhibitors of the nicotinic receptor-gated cation channel. J Pharmacol Exp Ther 1988; 244:963-970
38. Vincent JP, Cavey D, Kamenka JM, Geneste P, Lazdunski M: Interaction of phencyclidines with the muscarinic and opiate receptors in the central nervous system. Brain Res 1978; 152:176-182
39. Becher CE: Sernylan inhibition of primate serum cholinesterase. Clin Chem 1969; 45:780-781
40. 3H]phencyclidine binding in rat central nervous system. Proc Natl Acad Sci USA 1979; 76:5372-5376
41. Vincent JP, Kartalovski B, Geneste P, Kamenka JM, Lazdunski M: Interaction of phencyclidine ("angel dust") with a specific receptor in rat brain membranes. Proc Natl Acad Sci USA 1979; 76:4678-4682
42. Sircar RM, Rappaport M, Nichtenhauser R, Zukin SR: The novel anticonvulsant MK-801: a potent and specific ligand of the brain phencyclidine/σ-receptor. Brain Res 1987; 435:235-240
43. 3H]MK-801 labels a site on the N-methyl-D-aspartate receptor channel complex in rat brain membranes. J Neurochem 1988; 50:274-281
44. 3H)phencyclidine in rat central nervous tissue: further characterization and technical considerations. Brain Res 1983; 258:277-284
45. Javitt DC, Zukin SR: Role of excitatory amino acids in neuropsychiatric illness. J Neuropsychiatry Clin Neurosci 1990; 2:44-52
46. Snell LD, Yi S-J, Johnson KM: Comparison of the effects of MK-801 and phencyclidine on catecholamine uptake and NMDA-induced norepinephrine release. Eur J Pharmacol 1988; 145:223-226
47. Browne RG: Discriminative stimulus properties of PCP mimetics, in Phencyclidine: An Update. NIDA Research Monograph 64. Edited by Clouet D. Rockville, Md, National Institute on Drug Abuse, 1986
48. Willets J, Balster RL: Phencyclidine-like discriminative stimulus properties of MK-801 in rats. Eur J Pharmacol 1988; 146:167-169
49. Shannon HE: Evaluation of phencyclidine analogues on the basis of their discriminative stimulus properties in the rat. J Pharmacol Exp Ther 1981; 216:543-551
50. Johnson KM: Phencyclidine: behavioral and biochemical evidence supporting a role for dopamine. Fed Proc 1983; 42:2579-2583
51. Greenberg BD, Segal DS: Acute and chronic behavioral interactions between phencyclidine (PCP) and amphetamine: evidence for a dopaminergic role in some PCP-induced behaviors. Pharmacol Biochem Behav 1985; 23:99-105
52. Fessler RG, Sturgeon RD, Meltzer HY: Effects of phencyclidine and methylphenidate on d-amphetamine-induced behaviors in reserpine pretreated rats. Pharmacol Biochem Behav 1980; 13: 835-842
53. Carlsson M, Carlson A: The NMDA antagonist MK-801 causes marked locomotor stimulation in monoamine-depleted mice. J Neural Transm 1989; 75:221-226
54. Koek W, Colpaert FC, Woods JH, Kamenka J-M: The phencyclidine (PCP) analog N-[1[(2-Benzo(B)thiophenyl)cyclohexyl] piperidine shares cocaine-like but not other characteristic behav-ioral effects with PCP, ketamine and MK-801. J Pharmacol Exp Ther 1989; 250:1019-1027
55. Nieollon A, Krekerian L, Duticier N: Presynaptic controls in the neostriatum: reciprocal interactions between the nigro-striatal dopaminergic neurons and the cortico-striatal glutamatergic pathway. Exp Brain Res (suppl) 1983; 7:54-65
56. Scatton B, Worms P, Lloyd KG, Bartholini G: Cortical modulation of striatal function. Brain Res 1982; 232:331-343
57. Amalric M, Koob GF: Dorsal pallidum as a functional motor output of the corpus striatum. Brain Res 1989; 483:389-394
58. Pin JP, Van-Vliet BJ, Bockaert J: NMDA- and kainate-evoked GABA release from striatal neurones differentiated in primary culture: differential blocking by phencyclidine. Neurosci Lett 1988; 87:87-92
59. Donzanti BA, Uretsky NJ: Effects of excitatory amino acids on locomotor activity after bilateral microinjection into the rat nucleus accumbens: possible dependence on dopaminergic mechanisms. Neuropharmacology 1983; 22:971-981
60. Schmidt WJ: Intrastriatal injection of DL-2-amino-5 phosphonovaleric acid (AP-5) induces sniffing stereotypy that is antagonized by haloperidol and clozapine. Psychopharmacology (Berlin) 1986; 90:123-130
61. Chen G, Ensor CR, Bohner B: The neuropharmacology of 2-(ocholorphenyl)-2-methylaminocyclohexanone hydrochloride. J Pharmacol Exp Ther 1966; 152:332-339
62. Chen GM, Weston JK: The analgesic and anesthetic effect of 1(1-phenylcyclohexyl) piperidine-HCl on the monkey. Anesth Analg 1960; 39:132-137
63. Handelman GE, Contreras PC, O'Donohue TL: Selective memory impairment by phencyclidine in rats. Eur J Pharmacol 1987; 140:69-73
64. Balster RL, Chait LD: The behavioral pharmacology of phencyclidine. Clin Toxicol 1976; 9:513-528
65. Thompson DM, Winsauer PJ, Mastropaolo J: Effects of phencyclidine, ketamine and MDMA on complex operant behavior in monkeys. Pharmacol Biochem Behav 1987; 26:401-405
66. Thompson DM, Moerschbaecher JM: Phencyclidine in combination with d-amphetamine: differential effects on acquisition and performance of response chains in monkeys. Pharmacol Biochem Behav 1984; 20:619-627
67. Butelman ER: A novel NMDA antagonist, MK-801, impairs performance in a hippocampal-dependent spatial learning task. Pharmacol Biochem Behav 1989; 34:13-16
68. Moerschbaecher JM, Thompson DM: Differential effects of prototype opioid agonists on the acquisition of conditional discriminations in monkeys. J Pharmacol Exp Ther 1983; 226: 738-748
69. Kay SR, Fiszbein A, Opler LA: The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13:261-276
70. Andreasen NC, Olsen S: Negative v positive schizophrenia: definition and validation. Arch Gen Psychiatry 1982; 39:789-794
71. Angrist B, Sathananthan G, Wilk S, Gershon S: Amphetamine psychosis: behavioral and biochemical aspects. J Psychiatr Res 1974; 11:13-23
72. Griffith JD, Cavanaugh J, Held J, Oates JA: Dextroamphetamine: evaluation of psychotomimetic properties in man. Arch Gen Psychiatry 1972; 26:97-100
73. Bell DS: Comparison of amphetamine psychosis and schizophrenia. Br J Psychiatry 1965; 701-707
74. Schneider K: Clinical Psychopathology. New York, Grune & Stratton, 1959
75. Henn FA: Dopamine: a role in psychosis or schizophrenia, in Schizophrenia as a Brain Disease. Edited by Henn FA, HA Nasrallah. New York, Oxford University Press, 1982
76. Carpenter WT, Strauss JS, Muleh S: Are there pathognomonic symptoms in schizophrenia? an empiric investigation of Schneider's first-rank symptoms. Arch Gen Psychiatry 1973; 28: 847-852
77. Bleuler EP: Dementia Praecox or the Group of Schizophrenias (1908). Translated by Zinkin J. New York, International Universities Press, 1950
78. Bilder RM, Mukherjee S, Rieder RO, Pandurangi AK: Symptomatic and neuropsychological components of defect states. Schizophr Bull 1985; 11:409-419
79. Meltzer HY: Effects of neuroleptics on the schizophrenic syndrome, in Clinical Pharmacology in Psychiatry: Selectivity in Psychotropic Drug Action-Promises or Problems? Edited by Dahl SG, Gram LF, Paul SM, Potter WZ. New York, Springer-Verlag, 1987
80. Kay SR, Sevy S: Pyramidical model of schizophrenia. Schizophr Bull 1990; 16:537-545
81. Crow TJ, Ball J, Bloom SR, Brown R, Bruton CJ, Colter N, Frith CD, Johnstone EC, Owens DG, Roberts GW: Schizophrenia as an anomaly of development of cerebral asymmetry: a postmortem study and a proposal concerning the genetic basis of the disease. Arch Gen Psychiatry 1989; 12:1145-1150
82. Brown RG, Marsden CD: Cognitive function in Parkinson's disease: from description to theory. Trends Neurosci 1990; 13:21-29
83. Weinberger DR, Berman KF, Illowsky BP: Physiological dysfunction of dorsolateral prefrontal cortex in schizophrenia, III: a new cohort and evidence for a monoaminergic mechanism. Arch Gen Psychiatry 1988; 45:609-615
84. Kleinman JE, Casanova FM, Jaskiv GE: The neuropathology of schizophrenia. Schizophr Bull 1988; 14:209-216
85. 3H]MK-801 binding in Alzheimer's disease. J Neurochem 1989; 53:698-704
86. Quirion R, Bayorh MS, Zerbe RL, Pert CV: Evidence for an endogenous peptide ligand for the phencyclidine receptor. Peptides 1984; 5:967-973
87. Zukin SR, Zukin RS, Vale W, Rivier J, Nichtenhauser R, Snell LD, Johnson KM: An endogenous ligand of the brain σ/PCP receptor antagonizes NMDA-induced neurotransmitter release. Brain Res 1987; 416:84-89
88. Young AB, Greeamyre JT, Hollingsworth Z, Albin R, D'Amato C, Shoulson I, Penney JB: NMDA receptor losses in putamen from patients with Huntington's disease. Science 1988; 241: 981-983
89. Mirsky AF, Duncan CC: Etiology and expression of schizophrenia: neurobiological and psychosocial factors. Ann Rev Psychol 1986; 37:291-319
90. Ingvar DH, Franzen G: Abnormalities of cerebral bood flow distribution in patients with chronic schizophrenia. Acta Psychiatr Scand 1974; 50:425-462
91. Weinberger DR, Berman KF: Speculation on the meaning of metabolic "hypofrontality" in schizophrenia. Schizophr Bull 1988; 14:157-168
92. Pfefferbaum A, Ford JM, White PM, Roth WT: P3 in schizophrenia is affected by stimulus modality, response requirements, medication status, and negative symptoms. Arch Gen Psychiatry 1989; 46:1035-1044
93. Javitt DC, Schroeder CS, Arezzo JC, Vaughan HG Jr: Selective inhibition of processing-contingent auditory event-related potential components by the PCP-like agent MK-801. Electroencephalogr Clin Neurophysiol (in press)
94. Waziri R: Glycine therapy of schizophrenia (letter). Biol Psychiatry 1988; 23:210-211
95. Rosse RB, Theut SK, Banay-Schwartz M, Leighton M, Scarcella E, Cohen CG, Deutsch SI: Glycine adjuvant therapy to conventional neuroleptic treatment in schizophrenia: an open-label, pilot study. Clin Neuropharmacol 1989; 12:416-424